DOSAGE · RESEARCH CONTEXT ONLY
Dosing context for the GLOW constituents
There is no validated or standardized dose for the GLOW blend. What follows is constituent-level research data and handling chemistry, reported in the species and routes where it was studied — never a human dosing instruction.
Dosing in the Research Literature (No Validated Human Dose)
Glow peptide dosage cannot be stated as a human dose, because the blend has never been dosed in a controlled human trial [9]. Every figure below is either constituent-level research data or a non-validated supplier convention, presented for context only and never as a recommendation.
The constituent research figures are as follows. GHK-Cu drove fibroblast collagen synthesis in vitro at roughly 10^-12 to 10^-9 M, and topical cosmetic formulations sit at approximately 0.05% to 2% by weight [1]. BPC-157 rodent tissue-repair studies used roughly 10 ng to 10 microg per rat per day intraperitoneally; the transected-tendon study tested 10 microg, 10 ng or 10 pg per kg body weight [3]. For TB-500, most human work uses full-length thymosin beta-4 rather than the 7-mer fragment [6]. A commonly cited research-label blend ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial — a supplier labeling convention, not a clinically validated dose [9].
Routes Studied for the Constituent Peptides
Talk of a glow peptide injection runs ahead of the evidence, because the routes in the literature are constituent routes, not blend routes. GHK-Cu is predominantly studied topically — creams, serums, microneedle and liposomal delivery — with rodent intraperitoneal and intranasal systemic studies [1][2]. BPC-157 was given intraperitoneally and intramuscularly in animals [3]. Thymosin beta-4 was applied topically and intraperitoneally in animal wound work [5].
Community GLOW protocols describe subcutaneous injection of the reconstituted blend, but no peer-reviewed pharmacology supports subcutaneous blend dosing, and the combination has never been characterized as a unit [9]. Half-life is equally constituent-specific: BPC-157 has a short elimination half-life — under 30 minutes in rats and dogs — with rapid breakdown to amino acids, while topical GHK-Cu forms a longer-lived dermal copper depot. Whether co-formulation alters any constituent's kinetics is unstudied.
Reconstitution and handling chemistry
Lyophilized BPC-157 and TB-500 are reconstituted with bacteriostatic water and refrigerated. The GHK-Cu complex is most stable near pH 5 to 6.5, and its blue-violet color indicates an intact Cu(II) complex; strong reducing agents and low-pH actives such as ascorbic acid can break it.
Blend stability is formulation-specific and not characterized in the literature. Co-formulating a copper complex with two other peptides raises theoretical compatibility questions — copper redox chemistry and pH — that have not been studied for GLOW specifically. These notes describe research handling, not a preparation a reader should perform.
What human data exists, and what it does not cover
There is no human dosing data for the GLOW blend, and the human data on the individual constituents is itself limited. For GHK-containing formulations, the human record is small topical dermatology work plus a single hair-loss trial [1][8]. For BPC-157, only three small pilot studies have examined it in humans — intraarticular knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetics study — with no adverse effects reported but no large-scale trials, leading a 2025 review to classify BPC-157 as investigational [10]. For TB-500, most human work uses full-length thymosin beta-4 rather than the marketed 7-mer fragment, so it is not established that the fragment reproduces the parent protein's effects [6].
None of that supports a blend dose. A 2026 Sports Medicine review naming all three constituents concluded that these unapproved peptides show animal-model promise but scarce human safety data and potential for harm [9]. Because two constituents — BPC-157 and TB-500 — are also prohibited in sport by the World Anti-Doping Agency at all times, the assembled blend is off-limits for tested athletes regardless of any dosing question.